NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

脊髓性肌萎縮症 (SMA) 治療的全球市場:各類型,不同治療,各給藥途徑的市場調查,預測(∼2025年),COVID-19的累積性的影響

Spinal Muscular Atrophy Treatment Market Research Report by Type, by Treatment, by Route of Administration, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

出版商 360iResearch LLP 商品編碼 1005113
出版日期 內容資訊 英文 191 Pages
商品交期: 最快1-2個工作天內
價格
脊髓性肌萎縮症 (SMA) 治療的全球市場:各類型,不同治療,各給藥途徑的市場調查,預測(∼2025年),COVID-19的累積性的影響 Spinal Muscular Atrophy Treatment Market Research Report by Type, by Treatment, by Route of Administration, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19
出版日期: 2021年06月01日內容資訊: 英文 191 Pages
簡介

全球脊髓性肌萎縮症 (SMA) 治療的市場規模預計將從2020年的10 億 5,436 從萬美元,擴大到2025年末的20 億 6,321萬美元。

COVID-19是前所未有的全球性公共衛生突發事件,已影響到每個行業。這種長期影響預計將在預測期內影響行業增長。我們正在進行的研究正在擴大我們的研究範圍,以確保我們窮究潛在的COVID-19問題和未來路徑。該報告考慮了消費者行為和需求的變化,購買方式,供應鏈的重新改道,當前市場趨勢以及政府的重要介入等因素,提供有關COVID-19的洞察,分析,與預測。

 

這份報告提供脊髓性肌萎縮症 (SMA) 治療的世界市場調查,提供市場概要,市場成長要素及阻礙因素分析,市場機會,COVID-19的影響,類型·治療·給藥途徑·各地區的市場規模的變化與預測,競爭情形,主要企業的簡介等系統性資訊。

目錄

第1章 序文

  • 調查的目的
  • 市場區隔和涵蓋範圍
  • 調查涵蓋年份
  • 貨幣和價格
  • 語言
  • 限制事項
  • 相關利益者

第2章 調查手法

  • 調查流程
    • 定義:調查目的
    • 決策:調查設計
    • 準備:調查設備
    • 收集: 資料來源
    • 分析: 資料解釋
    • 制定: 資料檢驗
    • 發行:調查報告書
    • 反復: 報告的更新
  • 調查實施
    • 開始:調查流程
    • 計劃:調查計劃的制定
    • 實行:調查的實施
    • 檢驗: 發現與分析
    • 發行:調查報告書
  • 調查成果

第3章 摘要整理

  • 市場預測
  • 類型預測
  • 治療預測
  • 給藥途徑預測
  • 地區預測
  • 其他競爭公司預測

第4章 市場概要

  • COVID-19的累積性的影響

第5章 市場洞察

  • 市場動態
    • 促進因素
    • 阻礙因素
    • 市場機會
    • 課題
  • 波特的五力分析
    • 新加入廠商業者的威脅
    • 替代品的威脅
    • 客戶談判力
    • 供給企業談判力
    • 產業的競爭

第6章 各類型

  • 類型1
  • 類型2
  • 類型3
  • 類型4

第7章 不同治療

  • 藥物療法
  • 遺傳基因置換療法

第8章 各給藥途徑

  • 鞘內
  • 口服

第9章 南北美洲

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章 亞太地區

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 韓國
  • 泰國

第11章 歐洲,中東·非洲

  • 法國
  • 德國
  • 義大利
  • 荷蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 阿拉伯聯合大公國
  • 英國

第12章 競爭情形

  • FPNV 定位 矩陣
    • 象限
    • 事業策略
    • 產品滿意度
  • 市場排行榜分析
  • 市場佔有率分析
  • 其他競爭公司的SWOT分析
  • 競爭模式
    • 合併和收購
    • 協定,合作,夥伴關係
    • 新產品的銷售與強化
    • 投資與資金籌措
    • 獎,獎勵,擴大

第13章 企業的實用性簡介

  • Biogen Inc.
  • Cytokinetics, Inc.
  • F. Hoffmann-La Roche AG
  • Ionis Pharmaceuticals, Inc.
  • Isis Pharmaceuticals, Inc.
  • Novartis International AG
  • Pfizer Inc.
  • PTC Therapeutics

第14章 附錄

  • 討論指南
  • 許可證和價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MRR-0309FBC512FB

The Global Spinal Muscular Atrophy Treatment Market size was estimated at USD 1,054.36 Million in 2020 and expected to reach USD 1,211.14 Million in 2021, at a Compound Annual Growth Rate (CAGR) 15.20% to reach USD 2,465.39 Million by 2026.

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Spinal Muscular Atrophy Treatment to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Type, the Spinal Muscular Atrophy Treatment Market was studied across Type 1, Type 2, Type 3, and Type 4.

Based on Treatment, the Spinal Muscular Atrophy Treatment Market was studied across Drug Therapy and Gene Replacement Therapy.

Based on Route of Administration, the Spinal Muscular Atrophy Treatment Market was studied across Intrathecal and Oral.

Based on Geography, the Spinal Muscular Atrophy Treatment Market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific is further studied across China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Spinal Muscular Atrophy Treatment Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Spinal Muscular Atrophy Treatment Market, including Astellas Pharma Inc., AstraZeneca PLC, Biogen Inc., Boehringer Ingelheim GmbH, Catalyst Pharmaceuticals, Chugai Pharmaceutical, Cure SMA, Cytokinetics, Inc., F. Hoffmann-La Roche AG, Genentech, Inc, Genzyme Corporation, Ionis Pharmaceuticals, Inc., Isis Pharmaceuticals, Inc., Natera, Inc, Novartis International AG, Novo Nordisk A/S, PerkinElmer, Inc., Pfizer Inc., PTC Therapeutics, Regeneron Pharmaceuticals, Inc., Salarius Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, and UW Health.

The report provides insights on the following pointers:

  • 1. Market Penetration: Provides comprehensive information on the market offered by the key players
  • 2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
  • 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
  • 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
  • 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

  • 1. What is the market size and forecast of the Global Spinal Muscular Atrophy Treatment Market?
  • 2. What are the inhibiting factors and impact of COVID-19 shaping the Global Spinal Muscular Atrophy Treatment Market during the forecast period?
  • 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Spinal Muscular Atrophy Treatment Market?
  • 4. What is the competitive strategic window for opportunities in the Global Spinal Muscular Atrophy Treatment Market?
  • 5. What are the technology trends and regulatory frameworks in the Global Spinal Muscular Atrophy Treatment Market?
  • 6. What is the market share of the leading vendors in the Global Spinal Muscular Atrophy Treatment Market?
  • 7. What modes and strategic moves are considered suitable for entering the Global Spinal Muscular Atrophy Treatment Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

  • 3.1. Introduction
  • 3.2. Market Outlook
  • 3.3. Type Outlook
  • 3.4. Treatment Outlook
  • 3.5. Route of Administration Outlook
  • 3.6. Geography Outlook
  • 3.7. Competitor Outlook

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising burden of spinal muscular atrophy
      • 5.1.1.2. R&D initiatives for the potential treatment by companies
      • 5.1.1.3. Awareness programs initiatives by government and nonprofit organizations
    • 5.1.2. Restraints
      • 5.1.2.1. Limited time-window for successful therapy delivery
    • 5.1.3. Opportunities
      • 5.1.3.1. Joint development programs by market players
      • 5.1.3.2. Expansion of distribution channels particularly in developing countries
    • 5.1.4. Challenges
      • 5.1.4.1. Limited access for the treatment of SMA
  • 5.2. Cumulative Impact of COVID-19
  • 5.3. Porters Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry

6. Spinal Muscular Atrophy Treatment Market, by Type

  • 6.1. Introduction
  • 6.2. Type 1
  • 6.3. Type 2
  • 6.4. Type 3
  • 6.5. Type 4

7. Spinal Muscular Atrophy Treatment Market, by Treatment

  • 7.1. Introduction
  • 7.2. Drug Therapy
  • 7.3. Gene Replacement Therapy

8. Spinal Muscular Atrophy Treatment Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Intrathecal
  • 8.3. Oral

9. Americas Spinal Muscular Atrophy Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States
    • 9.6.1. California
    • 9.6.2. Florida
    • 9.6.3. Illinois
    • 9.6.4. New York
    • 9.6.5. Ohio
    • 9.6.6. Pennsylvania
    • 9.6.7. Texas

10. Asia-Pacific Spinal Muscular Atrophy Treatment Market

  • 10.1. Introduction
  • 10.2. China
  • 10.3. India
  • 10.4. Indonesia
  • 10.5. Japan
  • 10.6. Malaysia
  • 10.7. Philippines
  • 10.8. South Korea
  • 10.9. Thailand

11. Europe, Middle East & Africa Spinal Muscular Atrophy Treatment Market

  • 11.1. Introduction
  • 11.2. France
  • 11.3. Germany
  • 11.4. Italy
  • 11.5. Netherlands
  • 11.6. Qatar
  • 11.7. Russia
  • 11.8. Saudi Arabia
  • 11.9. South Africa
  • 11.10. Spain
  • 11.11. United Arab Emirates
  • 11.12. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
    • 12.1.1. Quadrants
    • 12.1.2. Business Strategy
    • 12.1.3. Product Satisfaction
  • 12.2. Market Ranking Analysis
  • 12.3. Market Share Analysis, By Quadrant
  • 12.4. Market Share Analysis, By Company
  • 12.5. Competitive Scenario
    • 12.5.1. Merger & Acquisition
    • 12.5.2. Agreement, Collaboration, & Partnership
    • 12.5.3. New Product Launch & Enhancement
    • 12.5.4. Investment & Funding
    • 12.5.5. Award, Recognition, & Expansion

13. Company Usability Profiles

  • 13.1. Astellas Pharma Inc.
  • 13.2. AstraZeneca PLC
  • 13.3. Biogen Inc.
  • 13.4. Boehringer Ingelheim GmbH
  • 13.5. Catalyst Pharmaceuticals
  • 13.6. Chugai Pharmaceutical
  • 13.7. Cure SMA
  • 13.8. Cytokinetics, Inc.
  • 13.9. F. Hoffmann-La Roche AG
  • 13.10. Genentech, Inc
  • 13.11. Genzyme Corporation
  • 13.12. Ionis Pharmaceuticals, Inc.
  • 13.13. Isis Pharmaceuticals, Inc.
  • 13.14. Natera, Inc
  • 13.15. Novartis International AG
  • 13.16. Novo Nordisk A/S
  • 13.17. PerkinElmer, Inc.
  • 13.18. Pfizer Inc.
  • 13.19. PTC Therapeutics
  • 13.20. Regeneron Pharmaceuticals, Inc.
  • 13.21. Salarius Pharmaceuticals, Inc.
  • 13.22. Takeda Pharmaceutical Company Limited
  • 13.23. UW Health

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing
  • 14.3. Contact Details

LIST OF FIGURES

  • FIGURE 1. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2020 VS 2026 (USD MILLION)
  • FIGURE 2. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2020 (USD MILLION)
  • FIGURE 3. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2020 (USD MILLION)
  • FIGURE 4. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2020 (USD MILLION)
  • FIGURE 5. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)
  • FIGURE 6. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET: MARKET DYNAMICS
  • FIGURE 7. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET: PORTERS FIVE FORCES ANALYSIS
  • FIGURE 8. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2020 VS 2026 (%)
  • FIGURE 9. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2020 VS 2026 (USD MILLION)
  • FIGURE 10. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2026
  • FIGURE 11. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 1, 2018-2026 (USD MILLION)
  • FIGURE 12. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 1, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 13. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 2, 2018-2026 (USD MILLION)
  • FIGURE 14. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 2, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 15. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 3, 2018-2026 (USD MILLION)
  • FIGURE 16. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 3, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 17. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 4, 2018-2026 (USD MILLION)
  • FIGURE 18. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 4, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 19. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2020 VS 2026 (%)
  • FIGURE 20. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2020 VS 2026 (USD MILLION)
  • FIGURE 21. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2026
  • FIGURE 22. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2026 (USD MILLION)
  • FIGURE 23. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG THERAPY, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 24. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GENE REPLACEMENT THERAPY, 2018-2026 (USD MILLION)
  • FIGURE 25. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GENE REPLACEMENT THERAPY, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 26. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2020 VS 2026 (%)
  • FIGURE 27. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2020 VS 2026 (USD MILLION)
  • FIGURE 28. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2026
  • FIGURE 29. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY INTRATHECAL, 2018-2026 (USD MILLION)
  • FIGURE 30. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY INTRATHECAL, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 31. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ORAL, 2018-2026 (USD MILLION)
  • FIGURE 32. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ORAL, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 33. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 34. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 35. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 36. ARGENTINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 37. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 38. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 39. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 40. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 41. CALIFORNIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 42. FLORIDA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 43. ILLINOIS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 44. NEW YORK SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 45. OHIO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 46. PENNSYLVANIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 47. TEXAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 48. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 49. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 50. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 51. CHINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 52. INDIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 53. INDONESIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 54. JAPAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 55. MALAYSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 56. PHILIPPINES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 57. SOUTH KOREA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 58. THAILAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 59. EUROPE, MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 60. EUROPE, MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 61. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 62. FRANCE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 63. GERMANY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 64. ITALY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 65. NETHERLANDS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 66. QATAR SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 67. RUSSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 68. SAUDI ARABIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 69. SOUTH AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 70. SPAIN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 71. UNITED ARAB EMIRATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 72. UNITED KINGDOM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 73. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET: FPNV POSITIONING MATRIX
  • FIGURE 74. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET: SHARE, BY QUADRANT, 2020
  • FIGURE 75. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET: SHARE, BY COMPANY, 2020
  • FIGURE 76. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE

LIST OF TABLES

  • TABLE 1. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET: MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
  • TABLE 3. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 4. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 1, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 5. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 2, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 6. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 3, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 7. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 4, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 8. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 9. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG THERAPY, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 10. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GENE REPLACEMENT THERAPY, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 11. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 12. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY INTRATHECAL, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 13. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ORAL, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 14. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 15. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 16. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 17. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 18. ARGENTINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 19. ARGENTINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 20. ARGENTINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 21. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 22. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 23. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 24. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 25. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 26. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 27. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 28. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 29. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 30. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 31. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 32. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 33. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 34. CALIFORNIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 35. CALIFORNIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 36. CALIFORNIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 37. FLORIDA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 38. FLORIDA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 39. FLORIDA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 40. ILLINOIS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 41. ILLINOIS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 42. ILLINOIS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 43. NEW YORK SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 44. NEW YORK SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 45. NEW YORK SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 46. OHIO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 47. OHIO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 48. OHIO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 49. PENNSYLVANIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 50. PENNSYLVANIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 51. PENNSYLVANIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 52. TEXAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 53. TEXAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 54. TEXAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 55. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 56. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 57. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 58. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 59. CHINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 60. CHINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 61. CHINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 62. INDIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 63. INDIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 64. INDIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 65. INDONESIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 66. INDONESIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 67. INDONESIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 68. JAPAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 69. JAPAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 70. JAPAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 71. MALAYSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 72. MALAYSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 73. MALAYSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 74. PHILIPPINES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 75. PHILIPPINES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 76. PHILIPPINES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 77. SOUTH KOREA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 78. SOUTH KOREA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 79. SOUTH KOREA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 80. THAILAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 81. THAILAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 82. THAILAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 87. FRANCE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 88. FRANCE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 89. FRANCE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 90. GERMANY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 91. GERMANY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 92. GERMANY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 93. ITALY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 94. ITALY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 95. ITALY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 96. NETHERLANDS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 97. NETHERLANDS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 98. NETHERLANDS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 99. QATAR SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 100. QATAR SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 101. QATAR SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 102. RUSSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 103. RUSSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 104. RUSSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 105. SAUDI ARABIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 106. SAUDI ARABIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 107. SAUDI ARABIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 108. SOUTH AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 109. SOUTH AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 110. SOUTH AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 111. SPAIN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 112. SPAIN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 113. SPAIN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 114. UNITED ARAB EMIRATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 115. UNITED ARAB EMIRATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 116. UNITED ARAB EMIRATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 117. UNITED KINGDOM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 118. UNITED KINGDOM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 119. UNITED KINGDOM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 120. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET: SCORES
  • TABLE 121. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET: BUSINESS STRATEGY
  • TABLE 122. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET: PRODUCT SATISFACTION
  • TABLE 123. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET: RANKING
  • TABLE 124. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET: SHARE, BY QUADRANT, 2020
  • TABLE 125. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET: SHARE, BY COMPANY, 2020
  • TABLE 126. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET: MERGER & ACQUISITION
  • TABLE 127. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
  • TABLE 128. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
  • TABLE 129. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET: INVESTMENT & FUNDING
  • TABLE 130. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET: AWARD, RECOGNITION, & EXPANSION
  • TABLE 131. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET: LICENSE & PRICING
  • TABLE 132. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET: CONTACT DETAILS